Università Degli Studi Di Bari

Itel Telecomunicazioni S.r.l.

Universita' Degli Studi “g.d.'annunzio”—chieti

Università Degli Studi Di Bari Aldo Moro

Universita' Degli Studi Di Chieti

Antonio Scilimati

Maria Grazia Perrone

Ernesto Santandrea

Paola Vitale

Leonardo Di Nunno

Paola Patrignani

Stefania Tacconelli

Marta Luciana Capone

Michele Diaferia

Domenico Tricarico

Liborio Stuppia

Ettore Porreca

The invention relates to a new class of compounds targeting COX-1. The invention also relates to the use of some of such compounds as a tool to investigate the structure and function of the enzyme, in the treatment targeting COX-1 or detection of COX-1 in relating disorders or diseases such as cancer and neuroinflammation, in particular in neurological (e.g. autism spectrum disorders) and neurodegenerative diseases (e.g. Alzheimer's diseases, Parkinson's diseases, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), traumatic brain injury (TBI), HIV dementia and prion diseases), and in gynecological tumor (e.g. ovarian cancer), neck and head tumor, and haematological tumors (e.g. multiple myeloma) and in the detection of COX-1 in 'in vitro' (cells and tissues) and in “in vivo”.

Mofezolac derivatives as multi-functions selective COX-1 inhibitors

The present invention relates to new compounds, ligands of the beta-3 adrenergic receptor, their preparation and their use in therapy or as research tools for said receptor; the invention also relates to a process for the preparation of the compounds of the invention and the use of inverse agonists of the beta-3 adrenergic receptor as medicaments.

Beta-3 receptor ligands and their use in therapy

Isoxazole derivatives, in particular diarylisoxazole derivatives inhibitors of cyclooxygenase (COX), in particular cyclooxygenase-1 (COX-1), their pharmaceutical compositions, the process for their preparation and their use for the chemoprevention and treatment of inflammatory syndromes and in the prevention and treatment of carcinomas, in particular intestinal, ovarian and cutaneous carcinomas, in the treatment of pain syndromes, in particular after surgery, and in the cardiovascular field as antithrombotics/vasoprotectives/cardioprotectives.

Functionalized diarylisoxazoles inhibitors of ciclooxygenase

Growing community of inventors

Bari, Italy

Antonio Scilimati